SRC and melanoma: Some outstanding c-Src inhibitors are: (I) Dasatinib, a dual Src/Abl TKI, FDA approved for chronic myeloid leukemia (CML) treatment, (II) Saracatinib13, currently in phase II clinical trials for the treatment of solid tumors, such as melanoma, prostate and gastric cancer, (III) Bosutinib14, a dual Src/Abl TKI, FDA approved for CML treatment15.